Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alogliptin/metformin - Takeda

Drug Profile

Alogliptin/metformin - Takeda

Alternative Names: Alogliptin benzoate/metformin hydrochloride; Inisync; KAZANO; Kazano; Metformin/alogliptin; Nesina Met; SYR-322/metformin; SYR-322MET; TAK-322/metformin; Vipdomet

Latest Information Update: 04 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics; Biguanides; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 04 Feb 2019 Chemical structure information added
  • 17 Aug 2017 Alogliptin/metformin market licensed to Hikma Pharmaceuticals in Middle East and North Africa
  • 28 Sep 2016 Registered for Type-2 diabetes mellitus in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top